Biology of Prostate Cancer

前列腺癌生物学

• 批准号: 9282702
• 负责人: KAREN E KNUDSEN
• 金额: $ 2.71万
• 依托单位: THOMAS JEFFERSON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-06-01 至 2018-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9282702
• 关键词: Biology; Breast; Cancer Biology; Cancer Center; Cessation of life; Clinical; Clinical Trials; Detection; Development; Diagnosis; Disease; Disease Management; Endocrine; Genitourinary system; Goals; Grant; Hormones; Institution; Instruction; Malignant - descriptor; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of prostate; Neoplasm Metastasis; Peer Review; Philadelphia; Physicians; Play; Prevention strategy; Prostate; Publications; Recruitment Activity; Research Personnel; Role; Scientist; Translating; Translational Research; United States; Universities; Urogenital Cancer; advanced disease; anticancer research; cancer prevention; cost; effective therapy; improved; male; novel; oncology; predictive marker; programs; treatment strategy; tumor progression; working group

PROJECT SUMMARY (See instructions): The Blology of Prostate Cancer (BPC) Program at the Kimmel Cancer Center (KCC) is a new program that emanated from the former Endocrine Mechanisms and Hormone Action in Cancer (EMHAC) Program, and represents the section of the EHMAC that focused on prostate cancer. From 2007 to 2011, EMHAC increased the number of highly productive investigators studying either breast/gynecological malignancies or prostate/genitourinary cancers, allow^ing the strategic creation of the BPC program in 2011. During this same interval, the Greater Philadelphia Prostate Cancer Working Group was founded by new recruit Dr. Karen Knudsen, and served as a basis for development of the BPC and the associated consortium. The BPC program consists of 18 investigators from 10 departments and 3 institutions. The Program currently brings in $2.3 million/year in total costs from NCI grants and $4.1 million/year total peer-reviewed costs. Since 2007, the program produced 343 publications of which, 10% of publications were intra-programmatic, 43% were inter-programmatic, and 5% were both inter- and intra-programmatic. Dr. Karen E. Knudsen (Leader) is an accomplished investigator with expertise in basic and translational prostate cancer research. Dr. Gomella, the Co-Leader (TJU) of BPC, provides clinical expertise in genitourinary malignancies. Dr. Fatatis the Co-leader (Drexel University) of BPC is an accomplished physician scientist with expertise in cancer metastasis at the basic and clinical level. He will play a pivotal role integrating Drexel University and TJU cancer researchers in the BPC Program. The goals of the BPC program are to leverage the significant translational and clinical expertise in genitourinary oncology (most especially with regard to prostate cancer) with the intent to: delineate the mechanisms that underpin prostate cancer development and progression, identify novel means to treat advanced disease, and improve disease management by translating these findings into clinical trials. Studies within the program are directed at developing new strategies for effective detection,diagnosis,and cure. Specific aims of this program are to;1. Develop new strategies for prevention, detection, and subtyping of early stage prostate malignancies; 2. Define the impact of hormone action in malignant disease development and prostate cancer progression; 3. Develop novel treatment strategies for prostate malignancies;4. Develop predictive markers for rational therapy delivery.

项目摘要（请参阅说明）： Kimmel Cancer Center（KCC）的前列腺癌（BPC）计划的BLOLOGY是一个新程序，它是从前内分泌机制和癌症中的激素作用（EMHAC）计划（EMHAC）计划（EMHAC）计划的新计划，代表了EHMAC的一部分，专注于前列腺癌。从2007年到2011年，EMHAC增加了研究乳房/妇科恶性肿瘤或前列腺/泌尿生殖器癌的高产研究人员的数量，允许在2011年制定BPC计划的战略创建。在此期间。 相同的间隔，大费城前列腺癌工作组是由新兵Karen Knudsen博士创立的，并作为BPC和相关财团发展的基础。 BPC计划由来自10个部门和3个机构的18位调查人员组成。该计划目前从NCI赠款中获得230万美元/年的总成本和410万美元的同行评审成本。 自2007年以来，该计划产生了343个出版物，其中10％的出版物是概括性的，有43％是策略截图，而5％的出版物均为典型和涉及过程中的5％。 Karen E. Knudsen博士（领导者）是一位有才华的研究者，在基本和转化前列腺癌研究方面具有专业知识。 BPC的共同领导者（TJU）Gomella博士提供了泌尿生殖器恶性肿瘤的临床专业知识。 BPC的共同领导者（Drexel University）是一位出色的医师科学家，在基本和临床水平上具有癌症转移方面的专业知识。他将扮演BPC计划中Drexel University和TJU癌症研究人员的关键角色。 BPC计划的目标是利用生殖肿瘤学（尤其是在前列腺癌方面）的重要转化和临床专业知识，其目的是：描述支撑前列腺癌的发展和进展的机制，确定治疗先进疾病的新方法，通过将这些发现来改善疾病管理，通过将这些发现转化为临床试验。该计划内的研究旨在制定有效检测，诊断和治愈的新策略。 该程序的具体目的为; 1。制定预防，检测和亚型的新策略的早期前列腺恶性肿瘤； 2。定义激素作用在恶性疾病发展和前列腺癌进展中的影响； 3。制定针对前列腺恶性肿瘤的新型治疗策略； 4。开发用于递送理性治疗的预测标记。